Leading brokers reiterate buy rating on this ASX healthcare share

Why ASX healthcare share Ansell Limited (ASX: ANN) has received a series of broker upgrades following its trading update

| More on:
asx shares to buy and hold represented by man happily hugging himself

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ansell Limited (ASX: ANN) share price has received a series of big broker share price updates following its trading update. Ansell has been a standout performer among ASX200 healthcare shares given its market leading position within the personal protective equipment sector. 

Ansell's trading update 

Ansell provided a trading update ahead of its 2020 AGM that should take place this week. The update upgraded its guidance for FY21, with the company experiencing continued strength in its business despite the continued uncertainties arising from COVID-19.

The update highlighted better than anticipated production volumes and sales across all five of its strategic business units, supplier cost increases being successfully managed, capex investments including capacity increases progressing to plan and more favourable exchange rates. Based on these developments, the company is now expecting organic growth to be in double digits and earnings per share (EPS) to be in the range of 135 to 145 cents (up from previous guidance of 126 to 138 cents). 

From an earlier capital markets presentation on 15 October, Ansell highlighted that global demand for exam and single use products had tripled. This was driven by healthcare, frontline workers and new hygiene protocols in other industries. It cited an estimated 370 billion gloves were currently produced annually, However, an estimated 585 billion gloves were needed, resulting in capacity increases taking place. 

Big broker upgrades 

Ansell was previously an underperforming ASX200 healthcare share that delivered minimal shareholder return throughout 2015 to 2020. COVID-19 has been a huge turning point for the business' growth trajectory.

Ansell has since received a series of broker upgrades as of Monday.

Citi retained its buy rating and a price target of $41.00. It was pleased with the better guidance on earnings and that company costs are under control. 

Credit Suisse raised its Ansell share price target from $43.00 to $45.00 and retains an outperform rating. It reacted positively to the FY21 upgrade, and upgrades expected earnings by 7% for FY21. 

Morgan Stanley retained an overweight rating and price target of $43.50. It notes solid progress on Ansell's costs despite increasing manufacturing capacity. 

Finally, UBS raised its Ansell share price target from $39.00 to $41.75 and retains a neutral rating. It was pleased with the company's increased operational efficiencies, organic growth and growth potential. However, it is cautious at its current valuation. 

Motley Fool contributor Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »